Two mitochondrial peptides sold and stacked as one move, each with a genuine and very different evidence story: one your own cells already make, and one the FDA just approved for an ultra-rare disease.
0
studies have ever combined them, in any species
1st
mitochondria-targeted drug ever approved (SS-31, 2025)
$800K/yr
for Forzinity, the only approved form of SS-31
2.16×
farther old mice ran on MOTS-c (still mice)
the short version
SS-31 earns its A on a deep, consistent record and a real FDA approval; MOTS-c earns its B on elegant biology that no human trial has ever tested; the stack is the cleanest pairing in the field, with the experiment that would confirm it still ahead. For most readers today, exercise plus the cheaper evidence-backed compounds is the more proven move than paying twice for a pairing nobody has tested. Revisit when NuPower and ReNEW report out on SS-31, and if anyone ever registers a trial that gives MOTS-c to a person.